Related Experiment Video
Updated: Mar 12, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
ITPP Treatment of RG2 Glioblastoma in a Rat Model
Karolina Förnvik1, Shaian Zolfaghari2, Leif G Salford2
1The Rausing Laboratory, Division of Neurosurgery, Department of Clinical Sciences Lund, Lund University, Lund, Sweden karolina.fornvik@med.lu.se.
Background:
Inositol trispyrophosphate (ITPP) has been shown to reduce tumour growth in different animal cancer models, as well as of human U87 glioma cells grafted onto chick chorioallantoic membrane (CAM). The aim of this study was to establish whether ITPP crosses the blood-brain barrier and whether it halts the growth of RG2 glioblastoma tumour.
Materials And Methods:
A model comprising of Fischer 344 rats was chosen and RG2 cells were implanted either intracranially, or subcutaneously on the left hind leg, and the animals were treated with ITPP either intraperitoneally, intravenously or both routes combined. Overall survival was then calculated.
Results:
No prolonged survival was seen in animals treated with ITPP. The route of ITPP administration did not affect outcome.
Conclusion:
ITPP had no favourable effect upon survival in our animal model with RG2 glioblastoma tumours in Fischer 344 rats.
Insights
Inositol trispyrophosphate (ITPP) did not improve survival in rats with RG2 glioblastoma tumors. This study investigated ITPP
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Inositol trispyrophosphate (ITPP) has demonstrated anti-tumor effects in various cancer models.
- Previous studies showed ITPP reduced human U87 glioma cell growth on chick chorioallantoic membrane (CAM).
Purpose of the Study:
- To determine if ITPP can cross the blood-brain barrier.
- To evaluate the efficacy of ITPP in halting RG2 glioblastoma tumor growth in vivo.
Main Methods:
- Fischer 344 rats were implanted with RG2 glioblastoma cells intracranially or subcutaneously.
- Animals received ITPP via intraperitoneal, intravenous, or combined administration routes.
- Overall survival was the primary endpoint assessed.
Main Results:
- ITPP administration did not lead to prolonged survival in rats bearing RG2 glioblastomas.
- The route of ITPP administration (intraperitoneal, intravenous, or combined) did not influence survival outcomes.
Conclusions:
- ITPP demonstrated no beneficial effect on survival in this Fischer 344 rat model of RG2 glioblastoma.
- Further research is needed to explore alternative therapeutic strategies for glioblastoma.
More Related Videos
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014